Darvadstrocel for perianal fistulae is reimbursed by European national health systems (Spain, France, Germany, Italy) following conditional EU approval, typically with gastroenterology authorisation. Systemic MSC remission therapy is not reimbursed by any major insurance scheme; classified as investigational. US insurance does not cover either indication. Out-of-pocket payment is standard for non-fistula MSC therapy; fistula therapy may be partially covered in EU depending on national formulary inclusion and prior authorisation criteria.
Darvadstrocel for perianal fistulae costs approximately €7,000–9,500 per application in European centres. Systemic MSC induction therapy for active Crohn's or ulcerative colitis costs €6,000–8,000 per infusion protocol. Multiple fistulae or combined induction+maintenance regimens escalate costs to €12,000–20,000+ per year. Insurance coverage varies significantly: EU approved indication (perianal fistulae) is reimbursed by several national healthcare systems (Spain, France, Germany) with prior authorisation; systemic IBD remission therapy is rarely covered, classified as investigational. Out-of-pocket payment is standard for non-fistula indications.
Съм ли кандидат? → · Crohn's & IBD: full overview → · Цена Болест на Крон и IBD → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка